< Back to all clusters
[BUSINESS] · Sweden · 2 sources

started · updated

Octave receives buy ratings from analysts following market sell-off

Analysts from Handelsbanken and SB1 Markets have issued buy recommendations for Octave following a period of market selling pressure. Despite a recent stock price decline triggered by its Q2 report and its recent spin-off from Hexagon, analysts suggest the market reaction was exaggerated.

Handelsbanken maintains a buy rating with a price target of 235 SEK, noting that while growth was softer than desired, margins exceeded expectations and recurring revenue continues to grow. SB1 Markets has raised its price target from 185 SEK to 200 SEK, citing the dissipation of initial spin-off selling pressure and an upward revision of 2026 adjusted earnings per share by 13 percent.

Entities

AstraZeneca · Handelsbanken · NCAB · Octave · SB1 Markets